Theravance Biopharma, Inc.TBPHNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank14
3Y CAGR+11.6%
5Y CAGR-21.4%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+11.6%/yr
vs -28.1%/yr prior
5Y CAGR
-21.4%/yr
Recent acceleration
Acceleration
+39.7pp
Accelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $111.07M | -0.2% |
| 2024 | $111.33M | +52.8% |
| 2023 | $72.84M | -8.9% |
| 2022 | $79.91M | -33.1% |
| 2021 | $119.44M | -67.7% |
| 2020 | $369.48M | +13.6% |
| 2019 | $325.33M | +9.0% |
| 2018 | $298.41M | +10.7% |
| 2017 | $269.48M | +19.1% |
| 2016 | $226.22M | - |